EMEA-000876-PIP07-15
Key facts
Invented name |
Soliris
|
Active substance |
Eculizumab
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0229/2016
|
PIP number |
EMEA-000876-PIP07-15
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Prevention of delayed graft function after solid organ transplantation
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Alexion Europe SAS
|
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|